Advertisement

Topics

Latest "ABL, Inc. and Aushon BioSystems" News Stories

10:20 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "ABL, Inc. and Aushon BioSystems" found in our extensive news archives from over 250 global news sources.

More Information about ABL, Inc. and Aushon BioSystems on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ABL, Inc. and Aushon BioSystems for you to read. Along with our medical data and news we also list ABL, Inc. and Aushon BioSystems Clinical Trials, which are updated daily. BioPortfolio also has a large database of ABL, Inc. and Aushon BioSystems Companies for you to search.

Showing "Aushon BioSystems" News Articles 1–25 of 124

Wednesday 20th March 2019

Benson Hill Biosystems Acquires Schillinger Genetics, Expanding High Quality Soybean Options

Benson Hill will deliver and expand the portfolio of soybean varieties with superior protein content and quality for human food and animal feed markets ST. LOUIS, MO—March 19, 2019—Benson Hill Biosystems, a crop improvement company unlocking the natural diversity of plants, announced today at the World Agri-Tech Innovation Summit that it has acquired the assets […] The post Benson Hill B...


Why T2 Biosystems Is A Potential 10X Bagger

Leica Biosytems now offers Innovative Circles cutting edge articles

The Leica Biosystems " Innoivators Circle" offers cutting edge articles committed to the latest advances in digital pathology. Read the fist issue now - Real-Time Focusing: Breakthrough Innovation in Optics. Leica Biosystems is always innovating across our 12 global Research and Development sites. Over the last several years, our digital pathology engineers in Pathology Imaging have approached man...


Tuesday 19th March 2019

Asuragen Portfolio Expansion Continues with Launch of AmplideX® PCR/CE SMN1/2 Kit

The kit enables the determination of SMN1 and SMN2 exon 7 copy number in less than four hours Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy-to-use products for complex testing in genetics and oncology, today announced the launch of the AmplideX® PCR/CE 

Thursday 7th March 2019

T2 Biosystems, Inc. (TTOO) CEO John McDonough on Q4 2018 Results - Earnings Call Transcript

Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2018

65% Q4 revenue growth; 65% full year growth Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months and twelve months ended Dec. 31, 2018. “This past quarter has been highly productive, capping off a strong year of a...

Wednesday 6th March 2019

T2 Biosystems Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

Secured 14 New Instrument Contracts in the Fourth Quarter and 39 total New Instrument Contracts in 2018 that are expected to drive growth in Recurring Test Revenue Confirms Guidance of a Doubling of Revenue in 2019; Provides Guidance of Securing 70 – 80 T2Dx Instruments Contracts in 2019 LEXINGTON, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the...

Tuesday 5th March 2019

UK biotech receives €1.5m to develop new class of antibiotic medicines

UK-based biotech company Procarta Biosystems has received €1.5 million funding to help it develop novel therapies to combat antimicrobial resistance (AMR).

Procarta announces €1.5 million investment for new class of antibiotics to combat antimicrobial resistance

Stevenage, UK, 5th March 2019 / Sciad Newswire / Procarta Biosystems, a privately held UK-based biotech company, today announced €1.5m of new funding from the Novo Holdings REPAIR Impact Fund to support development of novel therapies to combat antimicrobial resistance (AMR). The new funding will be used to develop a pipeline of an entirely new class of antibiotic […] The post Procarta a...

Why Hospitals Are Not Buying The T2 Biosystems Diagnostic System - $1.50 1-Year Price Target

Friday 1st March 2019

Drug resistance assay wins breakthrough device designation from FDA

The FDA granted breakthrough device designation to T2 Biosystems' T2Resistance Panel drug resistance blood test, which can de -More- 

LJL BioSystems, CRS Robotics Team to Accelerate Drug Discovery at Monsanto

LJL BioSystems Inc. (Sunnyvale, CA) and CRS Robotics Corp. (Toronto) have installed a state-of-the-art lab automation system at Monsanto (St. Louis) that combines LJL’s Analyst HT assay detection system with CRS’s robotics technology and Polara lab automation software...

Thursday 28th February 2019

FDA Grants Breakthrough Device Designation to T2 Biosystems’ T2Resistance Panel

LEXINGTON, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) — The FDA has granted T2 Biosystems, Inc. (NASDAQ:TTOO) “Breakthrough Device” designation for the T2Resistance Panel, a diagnostic panel that can detect 13 resistance genes from both gram-positive and gram-negative pathogens from a single patient blood sample, without the wait for blood culture. The 13 genes identified on the panel ̷...

Tuesday 26th February 2019

FDA Grants T2 Biosystems Breakthrough Device Designation for the T2Resistance™ Panel; Expected Availability through CE Mark in 2019

LEXINGTON, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- The FDA has granted T2 Biosystems, Inc. (NASDAQ:TTOO) “Breakthrough Device” designation for the T2Resistance Panel, a diagnostic panel that can detect 13 resistance genes from both gram-positive and gram-negative pathogens from a single patient blood sample, without the wait for blood culture. The 13 genes identified on the panel includ...

Wednesday 20th February 2019

T2 Biosystems to Present at the 8th Annual SVB Leerink Global Healthcare Conference

LEXINGTON, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to present at the 8th Annual SVB Leerink Global Healthcare Conference. The conference is ...

2019 Lifesciences BC Annual Award Winners Announced

LifeSciences BC is pleased to announce the recipients of the 21st Annual LifeSciences BC Awards, presented by FARRIS. These awards are presented annually to recognize talented individuals and organizations that represent the life sciences ecosystem in B.C. which includes; academia, health institutions, research & development, SMEs, government and indus...

Tuesday 19th February 2019

T2 Biosystems Announces 2018 Fourth Quarter and Full Year Financial and Operational Results Release and Conference Call Date

LEXINGTON, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it will release its 2018 fourth quarter and full year financial and operational results after the market closes on Thursday, March 7, 2019. In conjunction wi...

Empire Genomics Appoints New Leadership and Relocates Headquarters to Support Growing Demand from Clinical Laboratories Around the World

Company appoints industry veteran Andy Watson as Chief Executive Officer to build on recent 2018 successes and enable more customers to advance genetic research and improve patient care Empire Genomics Inc., the premier global provider of clinical and custom labeled molecular probes, today announced the appointments of Andy Watson as Chief Execu...

Saturday 16th February 2019

Applied Biosystems GeneAmp PCR System 9700 Thermal Cycler – NEEDS CALIBRATION

$399.90End Date: Sunday Mar-17-2019 15:00:24 PDTBuy It Now for only: $399.90Buy It Now | Add to watch list Biotech365 : Applied Biosystems GeneAmp PCR System 9700 Thermal Cycler – NEEDS CALIBRATION BioMarketplace You want to propose your products or a … Continue reading →

Thursday 14th February 2019

How proteins become embedded in a cell membrane

Many proteins with important biological functions are embedded in a biomembrane in the cells of humans and other living organisms. But how do they get in there in the first place? Researchers in the Department of Biosystems Science and Engineering at ETH Zurich investigated the matter. Nearly a thir...

Wednesday 6th February 2019

FALCO biosystems secure approval for MSI-IVD Kit in Japan

FALCO is working in collaboration with Promega microsatellite instability (MSI) chemistry and assay design and obtained the companion diagnostic approval. The MSI-IVD Kit from FALCO, detects MSI-High within The post FALCO biosystems secure approval for MSI-IVD Kit in Japan appeared first on Compelo Medical Devices.

Tuesday 5th February 2019

FALCO biosystems and Promega Corporation MSI-IVD Kit Collaboration Obtains Approved Companion Diagnostic Status in Japan

Promega Corporation today announced FALCO biosystems of Kyoto, Japan, a core business company of FALCO HOLDINGS, working in collaboration with Promega microsatellite instability (MSI) chemistry and assay design, obtained companion diagnostic approval for FALCO’s MSI-IVD from Japan’s regulatory agency, the Ministry of Health, Labour and W

Thursday 31st January 2019

Enhancing HD-MEA Systems with CMOS

At SfN 2018, we spoke to MaxWell Biosystems about their CMOS based HD-MEA systems for recording andstimulating electrogenic cells in-vitro - MaxOne and MaxTwo.

Monday 28th January 2019

PHC Holdings Signs Agreement to Acquire Anatomical Pathology Business from Thermo Fisher Scientific

PHC Holdings Corporation (headquarters: Tokyo, Japan, hereafter PHCHD) today announced that it has signed a definitive agreement with Thermo Fisher Scientific Inc. (NYSE: TMO) (hereafter Thermo Fisher), the world leader in serving science, to acquire Thermo Fisher’s Anatomical Pathology business for approximately US$ 1.14 billion. Thermo Fisher...

Tuesday 22nd January 2019

T2 Biosystems to Participate in Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria

LEXINGTON, Mass., Jan. 23, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that Tom Lowery, Ph.D., chief scientific officer, will present to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) on Wednesday, January 30, 2019, in Was...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks